Stem Cell Clinic

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

BRISBANE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 16, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).

Link:
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense

By Global News Feed

Saint Herblain (France), August 18, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that the U.S. Department of Defense (DoD) has decided not to exercise the second option year of the contract1 to supply Valneva’s Japanese encephalitis (JE) vaccine IXIARO®.

Read more:
Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense

Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review

By Global News Feed

Oslo, 18 August 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any safety concerns. Based on these results, the company plans to enroll up to three additional patients at the highest dose level.

Read the original:
Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated…

By Somatic Stem Cells

Planchard, D. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29, iv192iv237 (2018).

CAS PubMed Google Scholar

Ettinger, D. S. et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, 2020. J. Natl. Compr. Canc. Netw. 17, 14641472 (2019).

PubMed Google Scholar

Aggarwal, C. et al. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nat. Rev. Clin. Oncol. 18, 5662 (2021).

PubMed Google Scholar

Kunimasa, K. et al. Improvement strategies for successful next-generation sequencing analysis of lung cancer. Future Oncol. 16, 15971606 (2020).

CAS PubMed Google Scholar

Leighl, N. B. et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin. Cancer Res. 25, 46914700 (2019).

CAS PubMed Google Scholar

Saarenheimo, J., Andersen, H., Eigeliene, N. & Jekunen, A. Gene-guided treatment decision-making in non-small cell lung cancerA systematic review. Front. Oncol. 11, 754427 (2021).

PubMed PubMed Central Google Scholar

Rolfo, C. et al. Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer. J. Thorac. Oncol. 16, 16471662 (2021).

CAS PubMed Google Scholar

Laufer-Geva, S. et al. The clinical impact of comprehensive genomic testing of circulating cell-free DNA in advanced lung cancer. J. Thorac. Oncol. 13, 17051716 (2018).

PubMed Google Scholar

Woodhouse, R. et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE 15, e0237802 (2020).

CAS PubMed PubMed Central Google Scholar

Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548554 (2014).

CAS PubMed PubMed Central Google Scholar

Kukita, Y. et al. High-fidelity target sequencing of individual molecules identified using barcode sequences: De novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients. DNA Res. 22, 269277 (2015).

CAS PubMed PubMed Central Google Scholar

Casbon, J. A., Osborne, R. J., Brenner, S. & Lichtenstein, C. P. A method for counting PCR template molecules with application to next-generation sequencing. Nucl. Acids Res. 39, e81 (2011).

CAS PubMed PubMed Central Google Scholar

Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. U.S.A. 108, 95309535 (2011).

ADS PubMed PubMed Central Google Scholar

Akahori, D. et al. Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas. Sci. Rep. 11, 14999 (2021).

CAS PubMed PubMed Central Google Scholar

Takada, R. et al. Clinical utility of pancreatic cancer circulating tumor DNA in predicting disease progression, prognosis, and response to chemotherapy. Pancreas 49, e93e95 (2020).

CAS PubMed Google Scholar

Leon, S. A., Shapiro, B., Sklaroff, D. M. & Yaros, M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646650 (1977).

CAS PubMed Google Scholar

Mouliere, F. et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS ONE 6, e23418 (2011).

ADS CAS PubMed PubMed Central Google Scholar

Yamamoto, Y. et al. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. Cancer Sci. 110, 617628 (2019).

CAS PubMed PubMed Central Google Scholar

Liu, X. et al. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer. EBioMedicine 41, 345356 (2019).

PubMed PubMed Central Google Scholar

Underhill, H. R. et al. Fragment length of circulating tumor DNA. PLoS Genet. 12, e1006162 (2016).

PubMed PubMed Central Google Scholar

Liu, Y. et al. Increased detection of circulating tumor DNA by short fragment enrichment. Transl. Lung Cancer Res. 10, 15011511 (2021).

CAS PubMed PubMed Central Google Scholar

Mouliere, F. et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aat4921 (2018).

Article PubMed PubMed Central Google Scholar

Underhill, H. R. Leveraging the fragment length of circulating tumour DNA to improve molecular profiling of solid tumour malignancies with next-generation sequencing: A pathway to advanced non-invasive diagnostics in precision oncology?. Mol. Diagn. Ther. 25, 389408 (2021).

CAS PubMed PubMed Central Google Scholar

Li, F. et al. Ultra-short circulating tumor DNA (usctDNA) in plasma and saliva of non-small cell lung cancer (NSCLC) patients. Cancers (Basel) 12, 2041 (2020).

CAS Google Scholar

Heitzer, E., Auinger, L. & Speicher, M. R. Cell-free DNA and apoptosis: How dead cells inform about the living. Trends Mol. Med. 26, 519528 (2020).

CAS PubMed Google Scholar

Jahr, S. et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 16591665 (2001).

CAS PubMed Google Scholar

Jensen, T. J. et al. Whole genome bisulfite sequencing of cell-free DNA and its cellular contributors uncovers placenta hypomethylated domains. Genome Biol. 16, 78 (2015).

PubMed PubMed Central Google Scholar

Udomruk, S., Orrapin, S., Pruksakorn, D. & Chaiyawat, P. Size distribution of cell-free DNA in oncology. Crit. Rev. Oncol. Hematol. 166, 103455 (2021).

PubMed Google Scholar

Park, S. et al. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. Cancer 127, 30193028 (2021).

CAS PubMed Google Scholar

Stroun, M., Lyautey, J., Lederrey, C., Olson-Sand, A. & Anker, P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta 313, 139142 (2001).

CAS PubMed Google Scholar

Wang, B. G. et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 63, 39663968 (2003).

CAS PubMed Google Scholar

Avanzini, S. et al. A mathematical model of ctDNA shedding predicts tumor detection size. Sci. Adv. https://doi.org/10.1126/sciadv.abc4308 (2020).

Article PubMed PubMed Central Google Scholar

Ying, H. Q. et al. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC. Pharmacol. Res. 170, 105734 (2021).

CAS PubMed Google Scholar

Chen, Y. M. et al. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer 16, 868 (2016).

CAS PubMed PubMed Central Google Scholar

Garrido, P. et al. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Med. 10, 58785888 (2021).

CAS PubMed PubMed Central Google Scholar

Sueoka-Aragane, N. et al. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer Med. 10, 38733885 (2021).

CAS PubMed PubMed Central Google Scholar

Sakai, K. et al. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Mol. Oncol. 15, 126137 (2021).

CAS PubMed Google Scholar

Mok, T. S. et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629640 (2017).

CAS PubMed Google Scholar

Papadimitrakopoulou, V. A. et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 31, 15361544 (2020).

CAS PubMed Google Scholar

Oxnard, G. R. et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 4, 15271534 (2018).

PubMed Google Scholar

Wang, F. et al. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut 71, 13401349 (2021).

PubMed Google Scholar

Shaw, A. T. et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 374, 5461 (2016).

CAS PubMed Google Scholar

Blakely, C. M. et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat. Genet. 49, 16931704 (2017).

CAS PubMed PubMed Central Google Scholar

Mouliere, F. et al. Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. EMBO Mol. Med. 13, e12881 (2021).

CAS PubMed PubMed Central Google Scholar

Nagai, Y. et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 65, 727682 (2005).

CAS PubMed Google Scholar

Kukita, Y. et al. Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter. PLoS ONE 13, e0192611 (2018).

PubMed PubMed Central Google Scholar

Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 17541760 (2009).

CAS PubMed PubMed Central Google Scholar

Koboldt, D. C. et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568576 (2012).

CAS PubMed PubMed Central Google Scholar

Kukita, Y. et al. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS ONE 8, e81468 (2013).

ADS PubMed PubMed Central Google Scholar

Cao, Y., Xie, L., Xie, Y. & Xu, H. Sequential change-point detection via online convex optimization. Entropy 20, 108 (2018).

ADS PubMed Central Google Scholar

Link:
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated...

→←